ARCHIVES

Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening

April 25, 2014

DCE Proposes AIDS-Cancer Registry For Funding Through $2 Mil. Contract

April 9, 1993

DCE Board Approves Recompetition Concepts

March 18, 1988

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

May 30, 2014

NCI Stands Firm On Assist “Downscaling” Despite 150 Letters From States, Volunteers

January 15, 1993

Vanderbilt, Jonsson Centers Win NCI SPORE Grants.

May 18, 2001